Research Applications
Type 1 Diabetes (Approved — Essential)
Insulin is essential for survival in type 1 diabetes and remains irreplaceable. Modern management uses multiple daily injections or continuous subcutaneous insulin infusion (pump therapy).
Type 2 Diabetes (Approved)
Used when oral agents and GLP-1RAs fail to achieve glycemic control. Basal insulin (glargine, detemir, degludec) is typically added first, with bolus insulin for advanced disease.
Smart Insulin Research
Glucose-responsive "smart" insulin formulations that automatically adjust activity based on blood glucose levels are in clinical development.
Closed-Loop Artificial Pancreas
Automated insulin delivery systems coupling continuous glucose monitors with insulin pumps represent the frontier of diabetes technology.
Mechanism of Action
Insulin binds to the insulin receptor (IR), a receptor tyrosine kinase, triggering autophosphorylation and recruitment of IRS proteins (IRS-1/2). This activates two major pathways: PI3K/Akt for metabolic effects (GLUT4 translocation, glycogen synthesis, lipogenesis, protein synthesis) and Ras/MAPK for mitogenic effects (cell growth and differentiation). In muscle and adipose tissue, Akt-mediated GLUT4 translocation to the cell surface enables glucose uptake — the primary mechanism of blood glucose reduction.
Biological Pathways
IR/IRS/PI3K/Akt/GLUT4 for glucose uptake. Akt/GSK-3β for glycogen synthesis. Akt/mTOR/p70S6K for protein synthesis. Akt/FOXO for gluconeogenesis suppression. SREBP-1c for lipogenesis. Ras/Raf/MEK/ERK for cell growth.
Dosage Information
Calculation Results
Syringe Fill Level (100u syringe)
Protocols
No protocols featuring this peptide yet.
Browse All ProtocolsStability & Storage
Insulin must be stored at 2-8°C before opening. In-use insulin pens/vials can be stored at room temperature (up to 30°C) for 28-42 days depending on formulation. Never freeze. Sensitive to extreme heat and agitation. Modern analogs have improved stability profiles. Insulin is a relatively fragile protein requiring careful handling.
Side Effects & Precautions
Hypoglycemia is the most significant risk — severe hypoglycemia can cause seizures, loss of consciousness, and death. Weight gain (2-4 kg) is common with insulin initiation. Injection site lipohypertrophy from repeated injection in same site. Hypokalemia from insulin-mediated potassium shift. Rare allergic reactions. Insulin edema during initial treatment. Peripheral edema.
Research Use Only. This information is for educational and research purposes only. Not intended for medical advice or self-medication.
Regulatory Status
FDA-approved (multiple formulations): rapid-acting (lispro, aspart, glulisine), regular, intermediate (NPH), long-acting (glargine, detemir, degludec), ultra-long-acting, and premixed. Available worldwide. On WHO Essential Medicines List. WADA-prohibited unless medically prescribed for diagnosed diabetes.
Research Studies
The Discovery of Insulin
Banting FG, Best CH.
Insulin: Understanding its Action in Health and Disease
Wilcox G.
Related Peptides

Semaglutide
Ozempic, Wegovy +3 more

Tesamorelin
Tesamorelin Acetate, Egrifta +2 more

Tirzepatide
Mounjaro, Zepbound +2 more

AOD-9604
Advanced Obesity Drug 9604, hGH Fragment 176-191 +3 more

Retatrutide
LY3437943, Reta +1 more

Dulaglutide
Trulicity, LY2189265
